Alcohol
Volume 43, Issue 7 , Pages 559-563 , November 2009

Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives

  • Giovanni Addolorato

      Affiliations

    • Institute of Internal Medicine, “Agostino Gemelli” Hospital, Catholic University of Rome, Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-06-30154334; fax: +39-06-35502775.
    • ,
  • Lorenzo Leggio

      Affiliations

    • Institute of Internal Medicine, “Agostino Gemelli” Hospital, Catholic University of Rome, Rome, Italy
    • Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA
    • ,
  • Silvia Cardone

      Affiliations

    • Institute of Internal Medicine, “Agostino Gemelli” Hospital, Catholic University of Rome, Rome, Italy
    • ,
  • Anna Ferrulli

      Affiliations

    • Institute of Internal Medicine, “Agostino Gemelli” Hospital, Catholic University of Rome, Rome, Italy
    • ,
  • Giovanni Gasbarrini

      Affiliations

    • Institute of Internal Medicine, “Agostino Gemelli” Hospital, Catholic University of Rome, Rome, Italy

Received 17 December 2008 ,Revised 6 May 2009 ,Accepted 12 August 2009.

References 

  1. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence. Alcohol. Clin. Exp. Res. 2000;24:67–71
  2. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double blind randomized controlled study. Alcohol Alcohol. 2002;37:504–508
  3. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am. J. Med. 2002;112:226–229
  4. Addolorato G, Leggio L, Abenavoli L, DeLorenzi G, Parente A, Caputo F, et al. Suppression of alcohol delirium tremens by baclofen administration: a case-report. Clin. Neuropharmacol. 2003;26:258–262
  5. Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many craving? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005;51:59–66
  6. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am. J. Med. 2006;119:276.e13–276.e18
  7. Addolorato G, Leggio L, Agabio R, Colombo G, Gasbarrini G. Baclofen: a new drug for the treatment of alcohol dependence. Int. J. Clin. Pract. 2006;60:1003–1008
  8. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370:1915–1922
  9. Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L. Understanding and treating patients with alcoholic cirrhosis: an update. Alcohol. Clin. Exp. Res. 2009;33:1136–1144
  10. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005;40:147–150
  11. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol. Clin. Exp. Res. 1995;19:92–99
  12. Bormann J. The ‘ABC’ of GABA receptors. Trends Pharmacol. Sci. 2000;21:16–19
  13. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007;42:158–160
  14. Colombo G, Addolorato G, Agabio R, Carai MA, Pibiri F, Serra S, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox. Res. 2004;6:403–414
  15. Cryan JF, Kaupmann K. Don't worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol. Sci. 2005;26:36–43
  16. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol. Clin. Exp. Res. 2004;28:1517–1523
  17. Garbutt JC, Kampov-Polevoy A, Flannery B, Kalka-Juhl L, Gallop R. Placebo-controlled trial of baclofen in alcohol dependence. Alcohol. Clin. Exp. Res. 2007;31(s2):61A;[abstract at the 30th Annual Scientific Meeting of the Research Society on Alcoholism (RSA); Chicago, IL, 2007]
  18. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J. Subst. Abuse Treat. 2009;36:S15–S23
  19. Hall W, Zador DZ. The alcohol withdrawal syndrome. Lancet. 1997;349:1897–1900
  20. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999;33:181–214
  21. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol. Clin. Exp. Res. 2007;31:582–595
  22. Kraemer KL, Mayo-Smith MF, Calkins DR. Impact of age on the severity, course, and complications of alcohol withdrawal. Arch. Intern. Med. 1997;157:2234–2241
  23. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJ, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993;33:157–163
  24. Koob GF. Alcoholism: allostasis and beyond. Alcohol. Clin. Exp. Res. 2003;27:232–243
  25. Koob GF. A role for GABA mechanisms in the motivational effects of alcohol. Biochem. Pharmacol. 2004;68:1515–1525
  26. Leggio L, Ferrulli A, Cardone S, Malandrino N, Mirijello A, D'Angelo C, et al. Relationship between the hypothalamic–pituitary–thyroid axis and alcohol craving in alcohol-dependent patients. A longitudinal study. Alcohol. Clin. Exp. Res. 2008;32:2047–2053
  27. Leggio L, Ferrulli A, Cardone S, Miceli A, Kenna GA, Gasbarrini G, et al. Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcoholic patients: a longitudinal study. Alcohol. 2008;42:375–381
  28. Leggio L, Ferrulli A, Malandrino N, Miceli A, Capristo E, Gasbarrini G, et al. Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2008;32:450–458
  29. Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol. Rev. 2009;19:115–129
  30. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:1106–1117
  31. Leggio L, Malandrino N, Ferrulli A, Cardone S, Miceli A, Gasbarrini G, et al. Is cortisol involved in the alcohol-related fat mass impairment? A longitudinal clinical study. Alcohol Alcohol. 2009;44:211–215
  32. Maccioni P, Colombo G. Role of the GABAB receptor in alcohol seeking and drinking behavior: focus on preclinical studies. Alcohol. 2009;43:555–558
  33. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, Aguilar-Gaziola S, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict. Behav. 1998;23:893–907
  34. Millan MJ. The neurobiology and control of anxious states. Prog. Neurobiol. 2003;70:83–244
  35. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety and antidepressant-like behavior. Neuropsychopharmacology. 2004;29:1050–1062
  36. O'Connor PG, Schotternfeld RS. Patients with alcohol problems. N. Engl. J. Med. 1998;338:592–602
  37. Sajdyk TJ, Shekhar A, Donald R, Gehlert DR. Interactions between NPY and CRF in the amygdale to regulate emotionality. Neuropeptides. 2004;38:225–234
  38. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology. 2001;158:343–359
  39. Stallings W, Schrader S. Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. J. Okla. State Med. Assoc. 2007;100:354–360
  40. Swift RM, Stout RL. The relationship between craving, anxiety, and other symptoms in opioid withdrawal. J. Subst. Abuse. 1992;4:19–26
  41. Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999;34:197–222

 This mini-review summarizes a presentation at the meeting “Alcohol and Stress: A Framework for Future Treatment Strategies.” Volterra, Italy. May 6–8, 2008. This meeting was supported by a grant from the National Institute of Alcohol Abuse and Alcoholism (AA017581). This mini-review was partly supported by the European Research Advisory Board (ERAB).

PII: S0741-8329(09)00163-3

doi: 10.1016/j.alcohol.2009.09.031

Alcohol
Volume 43, Issue 7 , Pages 559-563 , November 2009

Article Tools